marked.bio

Company

Beijing Pearl Biotechnology

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

vebreltinib 2PLB1004 1osimertinib 1

Trials

3 of 4 trials shown

  1. A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

    Recruiting Phase 3 Beijing Pearl Biotechnology Started 2023Primary completion 2026-09 NCT05989542

    vebreltinib

    The presence of MET exon 14 jump mutation was confirmed by the NGS test in the central laboratory, and the 'Combined …

    MET exon 14 skippingNon-small Cell Lung Cancer

  2. A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

    Active, not recruiting Phase 2/3 Beijing Pearl Biotechnology Started 2018Primary completion 2023-04 NCT06105619

    vebreltinibtemozolomidecisplatinetoposide

    A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

    IDH1/2 mutationGlioblastoma

  3. A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

    Not yet recruiting Phase 1/2 Beijing Pearl Biotechnology Started 2026Primary completion 2029-12 NCT07285148

    PLB1004osimertinib FDA EU

    Have a documented EGFR positive mutation (EGFR classic mutations including ex19del and ex21 L858R, uncommon mutations and ex20 insertion mutations) in tumor tissue samples …

    EGFR exon 19 deletion / L858REGFR exon 20 insertionNon-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration